HoxD10 Antibody (B-10): sc-166233

HoxD10 Antibody (B-10) is a mouse monoclonal IgG1 antibody that detects HoxD10 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). HoxD10, a member of the Abd-B homeobox family, plays a crucial role in developmental processes by regulating gene expression that influences cellular differentiation and morphogenesis, particularly along the anterior-posterior body axis. This nuclear protein is predominantly expressed in the adult male and female urogenital tracts and is also found in developing limb buds, highlighting its importance in both reproductive and limb development. Notably, mutations in HoxD10 are linked to congenital vertical talus (CVT), a condition characterized by a dislocation of the talonavicular joint, often accompanied by other congenital deformities. HoxD10′s ability to direct DNA-protein and protein-protein interactions is essential for proper axial patterning, and dysregulation can lead to severe developmental disorders, making anti-HoxD10 antibody (B-10) a valuable tool for researchers studying developmental biology and related pathologies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

HoxD10 Antibody (B-10) References:

1. HOXD10 acts as a tumor-suppressive factor via inhibition of the RHOC/AKT/MAPK pathway in human cholangiocellular carcinoma.  |  Yang, H., et al. 2015. Oncol Rep. 34: 1681-91. PMID: 26260613
2. Decreased HoxD10 Expression Promotes a Proliferative and Aggressive Phenotype in Prostate Cancer.  |  Mo, RJ., et al. 2017. Curr Mol Med. 17: 70-78. PMID: 28231752
3. Silencing HOXD10 by promoter region hypermethylation activates ERK signaling in hepatocellular carcinoma.  |  Guo, Y., et al. 2017. Clin Epigenetics. 9: 116. PMID: 29075359
4. Epigenetic inactivation of HOXD10 is associated with human colon cancer via inhibiting the RHOC/AKT/MAPK signaling pathway.  |  Yuan, YH., et al. 2019. Cell Commun Signal. 17: 9. PMID: 30683109
5. Frequent promoter methylation of HOXD10 in endometrial carcinoma and its pathological significance.  |  Yang, F., et al. 2020. Oncol Lett. 19: 3602-3608. PMID: 32269635
6. Identification of HOXD10 as a Marker of Poor Prognosis in Glioblastoma Multiforme.  |  Li, Y., et al. 2021. Onco Targets Ther. 14: 5183-5195. PMID: 34737577
7. HOXD10 expression as a prognostic factor for hepatocellular carcinoma treated with curative resection.  |  Park, S., et al. 2021. J BUON. 26: 1942-1949. PMID: 34761603
8. Restoring HOXD10 Exhibits Therapeutic Potential for Ameliorating Malignant Progression and 5-Fluorouracil Resistance in Colorectal Cancer.  |  Pan, W., et al. 2021. Front Oncol. 11: 771528. PMID: 34790580
9. Prognostic and clinical significance of HOXC9 and HOXD10 in papillary thyroid cancer.  |  Cao, YM., et al. 2021. Transl Cancer Res. 10: 3317-3325. PMID: 35116638
10. HOXD10 attenuates renal fibrosis by inhibiting NOX4-induced ferroptosis.  |  Li, X., et al. 2024. Cell Death Dis. 15: 398. PMID: 38844470

The preferred HoxD10 antibody is HoxD10 Antibody (G-3): sc-166235.